Understanding CMC Strategy in Biologics: Impact on Future Outcomes

Upcoming Webinar on CMC Strategy in Biologics

In the intricate world of biologics, the decisions made during the early stages of development can have profound impacts later in the manufacturing process. A new webinar hosted by Xtalks is set to delve into this critical subject, emphasizing how strategic decisions made months in advance can significantly influence manufacturing efficiency and cost-effectiveness.

Join experts in the field as they discuss the common challenges faced in CMC (Chemistry, Manufacturing, and Controls). Many of these issues stem from choices made during essential phases such as cell line development and process design. Without a comprehensive understanding of the downstream consequences, these early decisions can lead to delays, increased costs, and complex regulatory hurdles that are time-consuming and expensive to rectify.

The session will highlight specific areas where CMC strategies frequently falter, including recurring decision points across manufacturing stages. Attendees will learn from seasoned professionals with over 25 years of experience in CMC management. They will share insights on prevalent development patterns, low-risk decisions that may turn costly, and early warning signs that differentiate startups poised for success from those struggling to maintain momentum.

With various programs having distinct needs, the webinar will address how different CMC priorities arise for teams racing against the clock for first-in-human trials compared to those preparing for phase transitions or optimizing underperforming processes. Participants will walk away with actionable strategies to match their CMC approach to their specific program stage and overall goals.

This session promises practical guidance for professionals aiming to make informed decisions, ultimately reducing downstream risks associated with biologics development. Don't miss the opportunity to learn from experts like Xiao-Ping Dai, PhD, Chief Technical Officer at Alveus Therapeutics, and Dr. Ellen Hilgenberg, Director of Business Development at ProBioGen, live on Thursday, September 10, 2026, at 10 AM EDT (4 PM CEST).

For registration details, participants can visit the Xtalks website where further information is available on this compelling topic: "CMC Strategy in Biologics: Decisions With Downstream Consequences."

About Xtalks

Xtalks is a leading platform designed to enable professionals from various sectors within the life sciences industry, including pharma, biotech, and medtech, to keep themselves informed and connected. With a wealth of resources including webinars, podcasts, and expert interviews, Xtalks provides essential industry insights. Thousands rely on their information each year to stay ahead of trends and issues that impact their work.

For more details on upcoming webinars and additional resources, visit www.xtalks.com.